NCT04579224 2026-03-19
Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
Clinical Trials
27 trialsNCT04039230 2026-03-16
Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.
Massachusetts General Hospital
Phase 1/2 Active not recruiting
NCT06133517 2026-03-16
PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer
Fundación para el Progreso de la Oncología en Cantabria
Phase 2 Active not recruiting
NCT06028932 2026-03-05
A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients
Yale University
Phase 2 Active not recruiting
NCT06100874 2026-02-24
A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT06178588 2026-02-24
Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma
University of Kansas Medical Center
Phase 2 Active not recruiting
NCT04251416 2026-02-17
A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma
Yale University
Phase 2 Active not recruiting
NCT05186974 2026-02-11
EVOKE-02
Gilead Sciences
Phase 2 Active not recruiting
NCT04639986 2026-02-09
Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)
Gilead Sciences
Phase 3 Active not recruiting
NCT04454437 2026-02-02
Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments
Gilead Sciences
Phase 2 Active not recruiting
NCT03964727 2026-01-30
TROPiCS-03
Gilead Sciences
Phase 2 Active not recruiting
NCT05327530 2026-01-26
A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)
EMD Serono
Phase 2 Active not recruiting
NCT04448886 2026-01-15
Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT06486441 2026-01-15
ASCENT-GYN-01
Gilead Sciences
Phase 3 Active not recruiting
NCT05609968 2025-12-24
MK-3475-D46
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT04863885 2025-12-17
Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Active not recruiting
NCT06612203 2025-12-05
WIN-B
MedSIR
Phase 1/2 Active not recruiting
NCT04595565 2025-11-25
SASCIA
GBG Forschungs GmbH
Phase 3 Active not recruiting
NCT05119907 2025-11-17
Study of Sacituzumab Govitecan in Patients With Solid Tumor
Gilead Sciences
Phase 2 Active not recruiting
NCT05675579 2025-11-04
A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05143229 2025-10-06
ASSET
University of Kansas Medical Center
Phase 1 Active not recruiting
NCT05840211 2025-10-03
ASCENT-07
Gilead Sciences
Phase 3 Active not recruiting
NCT05382299 2025-09-05
ASCENT-03
Gilead Sciences
Phase 3 Active not recruiting
NCT05089734 2025-05-23
EVOKE-01
Gilead Sciences
Phase 3 Active not recruiting
NCT03725761 2025-05-13
Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy
University of Wisconsin, Madison
Phase 2 Active not recruiting
NCT04647916 2025-04-24
Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases
SWOG Cancer Research Network
Phase 2 Active not recruiting
NCT05101096 2025-03-25
ASCENT-J02
Gilead Sciences
Phase 1/2 Active not recruiting